The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
Open accessAbstract
Purpose: Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental interactions for proliferation and survival that are at least partially mediated through B-cell receptor (BCR) signaling. Ibrutinib, a Bruton tyrosine kinase inhibitor, disrupts BCR signaling and leads to the egress of tumor cells from the microenvironment. Although the on-target effects on CLL cells are well defined, the impact on the microenvironment is less well studied. We therefore sought to characterize the in vivo effects of ibrutinib on the tumor microenvironment. Experimental Design: Patients received single-agent ibrutinib on an investigator-initiated phase II trial. Serial blood and tissue samples were collected pretreatment and during treatment. Changes in cytokine levels, cellular subsets, and microenvironmental interactions were assessed. Results: Serum levels of key chemokines and inflammatory cytokines decreased significantly in patients on ibrutinib. Furthermore, ibrutinib treatment decreased circulating tumor cells and overall T-cell numbers. Most notably, a reduced frequency of the Th17 subset of CD4+ T cells was observed concurrent with reduced expression of activation markers and PD-1 on T cells. Consistent with direct inhibition of T cells, ibrutinib inhibited Th17 differentiation of murine CD4+ T cells in vitro. Finally, in the bone marrow microenvironment, we found that ibrutinib disaggregated the interactions of macrophages and CLL cells, inhibited secretion of CXCL13, and decreased the chemoattraction of CLL cells. Conclusions: In conjunction with inhibition of BCR signaling, these changes in the tumor microenvironment likely contribute to the antitumor activity of ibrutinib and may impact the efficacy of immunotherapeutic strategies in patients with CLL. Clin Cancer Res; 22(7); 1572–82. ©2015 AACR. See related commentary by Bachireddy and Wu, p. 1547
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationHonigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Self-citationResistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · cited 1×
“However, continued therapywith ibrutinib is required, and some patients, especially those with adverse disease features may eventually develop resistance to ibrutinib (28).”
BackgroundSelf-citationDubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Self-citationPonader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Cited by
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
Treon, S. P., Castillo, J. J., Skarbnik, A. P., Soumerai, J. D., Ghobrial, I. M., Guerrera, M. L., Meid, K., & Yang, G. (2020) · Blood · doi:10.1182/blood.2020006288 · Cited by 909
Immunopathology of Hyperinflammation in COVID-19
Gustine, J. N., & Jones, D. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.08.009 · Cited by 516
Kipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G., O'Brien, S., Gribben, J., & Rai, K. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.96 · Cited by 517
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Burger, J. A., & Wiestner, A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.121 · Cited by 431
Self-citationIbrutinib treatment improves T cell number and function in CLL patients
Long, M., Beckwith, K., Do, P., Mundy, B. L., Gordon, A., Lehman, A. M., Maddocks, K. J., Cheney, C., Jones, J. A., Flynn, J. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89756 · Cited by 388
Self-citation
Metadata
- Authors
- Niemann, C. U., Herman, S. E. M., Maric, I., Gomez-Rodriguez, J., Biancotto, A., Chang, B. Y., Martyr, S., Stetler-Stevenson, M., Yuan, C. M., Calvo, K. R., Braylan, R. C., Valdez, J., Lee, Y. S., Wong, D. H., Jones, J., Sun, C., Marti, G. E., Farooqui, M. Z. H., & Wiestner, A.
- Venue
- Clinical Cancer Research
- Published
- 2016-03-31
- Volume
- 22
- Issue
- 7
- Pages
- 1572-1582
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2195033221
- Cited by
- 201
- References
- 5
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1965
- The paper
- Niemann, C. U., Herman, S. E. M., Maric, I., Gomez-Rodriguez, J., Biancotto, A., Chang, B. Y., Martyr, S., Stetler-Stevenson, M., Yuan, C. M., Calvo, K. R., Braylan, R. C., Valdez, J., Lee, Y. S., Wong, D. H., Jones, J., Sun, C., Marti, G. E., Farooqui, M. Z. H., & Wiestner, A. (2016). Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1965
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.